🔗 Share this article

A shadow market for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on communication apps, according to new investigations.

Experimental Treatment Gaining Traction Via Social Media

The experimental drug, which is still in clinical trials, is being advertised by social media influencers for its supposed weight-reducing effects. Followers are urged to message these accounts privately for supplier links, while also obtaining discount codes.

Thriving Commerce on Messaging Platforms

Separately, a flourishing trade exists on messaging services, where groups with numerous of participants share comparison photos, injection guides and claims of rapid UK delivery. Sellers market the substance there before redirecting buyers to WhatsApp for purchases.

Understanding The Experimental Drug

This medication is an investigational injectable developed by US drugmaker Eli Lilly. The treatment affects three gut hormones – GLP-1, GIP and glucagon. Early trials indicate it could assist patients reduce up to a quarter of their total weight. Nicknamed the “triple G”, the drug is being hailed digitally as the successor to Ozempic.

Healthcare Experts Express Concerns

Nevertheless, physicians and chemists have warned that the sale of what remains an unapproved medication in the United Kingdom is worrisome and could result in users injecting products of uncertain source.

Some professionals said the popularity for retatrutide could be connected to the rising cost of approved weight loss products such as Mounjaro.

Regulatory Status and Implementation

Selling retatrutide on social media or Telegram is illegal in the UK, as it is an unapproved drug that cannot be marketed or supplied for human use under the Human Medicines Regulations 2012.

Several content creators try to sidestep the rules by calling to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and supply can still violate medicines, advertising, and consumer laws, risking fines, legal action or prison.

Service Reaction and Content Removal

According to the social media company, the service has removed problematic content and prohibited associated keywords and query recommendations. The organization stated it was dedicated to maintaining the service secure and allocating resources in enhancing compliance measures.

Digital Trading Operations

Investigations also found groups with up to nine thousand participants marketing the experimental drug using the platform's built-in search feature, which functions like a online catalog. Typing “retatrutide” immediately brings up groups with thousands of users, populated with photos of weight loss, glowing reviews and detailed guides for preparing or administering at home.

Within minutes of entering one community, a vendor posted contact information, where the majority of purchases occur. The vendor provided an instruction manual and guaranteed shipping within 48 hours. When questioned whether the substance was authentic, one vendor responded: “You can’t be sure.” Another shared a image of a supposed laboratory certificate. Not one inquired about body mass, medical conditions or past usage.

Product Information and Costs

Within these groups, messages show dark colored parcels with Royal Mail labels, stating to include fresh supplies. One message stated: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, mixed at residence with sterile water, or pre-filled injectors typically priced at 160 pounds for 20 milligrams. When asked how much time a pen should last, sellers give contradictory answers ranging from a few weeks to “depends on your body”.

Platform Oversight and Security Actions

A spokesperson for Telegram said it actively monitored harmful content on its service including content that encouraged the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“People are administering materials they can’t verify. Although the research behind this drug is valid, these digital products may not contain what they claim,” stated a pharmacy expert, the director of pharmacy at a pharmacy service.

A medical professional of an online medical service linked the increase in demand to recent cost increases for authorized weight-loss medications such as Mounjaro. “With prices increasing, patients are using social media. But fake treatments are extremely dangerous. You can’t be certain what’s inside or whether the environment they were produced in was sterile,” she explained.

Her team has previously seen patients injured by self-injection from unconfirmed sources. “We recognize the frustration, but purchasing from Telegram or communication platforms is gambling with your health,” stated the doctor. “These materials could be contaminated or incorrectly dosed.”

Manufacturer Statement

A spokesperson from Eli Lilly stated the substance was in phase 3 research studies and had not been reviewed or approved by any regulatory agency globally. “Therefore at this time no one can sell [it] for personal consumption,” they explained, noting that any item “misleadingly claiming itself as a company investigational product not yet authorized … may expose patients to potentially significant health risks”.